combination therapy

• 

Adjuvant nivolumab plus ipilimumab for kidney cancer

By Sharon Deveson Kell|2022-08-01T12:14:50+00:001 Aug 2022|Drug treatments|

Adjuvant therapy is medication that is given after surgery to [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab for kidney cancer

• 

Health-related quality of life with lenvatinib in combination with everolimus

By Sharon Deveson Kell|2022-07-28T14:27:48+00:0028 Jul 2022|Drug treatments|

Maintaining good health-related quality of life is important for all [...]

Read More

Comments Off on Health-related quality of life with lenvatinib in combination with everolimus

• 

Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer

By Sharon Deveson Kell|2022-07-13T07:17:59+00:0013 Jul 2022|Drug treatments|

Preliminary results from the COSMIC-313 clinical trial have ben released. [...]

Read More

Comments Off on Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer

• 

ASCO 2022: Sequencing of kidney cancer medicines

By Sharon Deveson Kell|2022-06-21T14:19:37+00:0021 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology (ASCO)  Annual Meeting [...]

Read More

Comments Off on ASCO 2022: Sequencing of kidney cancer medicines

• 

Sequencing of treatments for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-06-14T08:25:47+00:0014 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology Annual Meeting earlier [...]

Read More

Comments Off on Sequencing of treatments for advanced/metastatic kidney cancer

• 

Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

By Sharon Deveson Kell|2022-06-08T10:36:43+00:008 Jun 2022|Drug treatments|

Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]

Read More

Comments Off on Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

Telaglenastat plus everolimus in advanced kidney cancer

By Sharon Deveson Kell|2022-05-18T07:59:04+00:0018 May 2022|Drug treatments|

This phase 2 clinical trial (ENTRATA) looked at how safe [...]

Read More

Comments Off on Telaglenastat plus everolimus in advanced kidney cancer

• 

Quality of life on lenvatinib plus pembrolizumab combination

By Sharon Deveson Kell|2022-05-17T07:35:28+00:0017 May 2022|Drug treatments|

In this study, the health-related quality of life (HRQoL) of [...]

Read More

Comments Off on Quality of life on lenvatinib plus pembrolizumab combination

• 

MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

By Sharon Deveson Kell|2022-05-11T07:43:47+00:0011 May 2022|Drug treatments|

MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]

Read More

Comments Off on MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer